Corporate Profile

Cortexyme is a biopharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is enrolling patients in a Phase 2/3 clinical trial of its lead small molecule in mild to moderate Alzheimer's disease.

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Investor Relations

News Releases

31 Jul '19
-- Presentation to be webcast on Cortexyme’s website SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 31, 2019-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and

Recent Events

Featured Reports

More information is coming soon.